
Feb 3 (Reuters) - Pfizer Inc PFE.N:
PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL
PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL
PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28
PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026
PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE
PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28
PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026
PFIZER: ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE
PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE